Jayvant Heera

1.5k total citations
43 papers, 992 citations indexed

About

Jayvant Heera is a scholar working on Virology, Infectious Diseases and Epidemiology. According to data from OpenAlex, Jayvant Heera has authored 43 papers receiving a total of 992 indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Virology, 29 papers in Infectious Diseases and 15 papers in Epidemiology. Recurrent topics in Jayvant Heera's work include HIV Research and Treatment (37 papers), HIV/AIDS drug development and treatment (27 papers) and HIV/AIDS Research and Interventions (18 papers). Jayvant Heera is often cited by papers focused on HIV Research and Treatment (37 papers), HIV/AIDS drug development and treatment (27 papers) and HIV/AIDS Research and Interventions (18 papers). Jayvant Heera collaborates with scholars based in United States, United Kingdom and Germany. Jayvant Heera's co-authors include Hernán Valdez, Winnie Dong, James Goodrich, Marilyn Lewis, Ian James, Conan K. Woods, P. Richard Harrigan, Natasa Rajicic, Luke C. Swenson and Howard Mayer and has published in prestigious journals such as PLoS ONE, Clinical Infectious Diseases and Annals of the New York Academy of Sciences.

In The Last Decade

Jayvant Heera

42 papers receiving 980 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jayvant Heera United States 18 771 700 254 146 124 43 992
Pauline Campa France 16 637 0.8× 592 0.8× 274 1.1× 142 1.0× 91 0.7× 28 914
Michael Wohlfeiler United States 14 637 0.8× 758 1.1× 280 1.1× 107 0.7× 209 1.7× 31 1.1k
Theresa Mo Canada 18 948 1.2× 943 1.3× 291 1.1× 171 1.2× 83 0.7× 33 1.2k
Maria Cecília Araripe Sucupira Brazil 18 646 0.8× 654 0.9× 252 1.0× 102 0.7× 45 0.4× 59 966
Mary O’Hearn United States 6 599 0.8× 676 1.0× 136 0.5× 115 0.8× 83 0.7× 9 838
Moti Ramgopal United States 21 901 1.2× 1.1k 1.6× 418 1.6× 250 1.7× 322 2.6× 83 1.5k
J Lange Netherlands 15 672 0.9× 623 0.9× 250 1.0× 110 0.8× 96 0.8× 23 910
Sidonie Lambert-Niclot France 21 1.1k 1.4× 1.1k 1.6× 241 0.9× 167 1.1× 185 1.5× 63 1.4k
Anna Cruceta Spain 15 796 1.0× 880 1.3× 267 1.1× 171 1.2× 162 1.3× 30 1.1k
Gilles Darcis Belgium 18 655 0.8× 584 0.8× 220 0.9× 203 1.4× 116 0.9× 70 1.1k

Countries citing papers authored by Jayvant Heera

Since Specialization
Citations

This map shows the geographic impact of Jayvant Heera's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jayvant Heera with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jayvant Heera more than expected).

Fields of papers citing papers by Jayvant Heera

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jayvant Heera. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jayvant Heera. The network helps show where Jayvant Heera may publish in the future.

Co-authorship network of co-authors of Jayvant Heera

This figure shows the co-authorship network connecting the top 25 collaborators of Jayvant Heera. A scholar is included among the top collaborators of Jayvant Heera based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jayvant Heera. Jayvant Heera is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Heera, Jayvant, Srinivas Rao Valluri, Charles Craig, et al.. (2019). First prospective comparison of genotypic versus phenotypic tropism assays in predicting virologic responses to maraviroc in a phase 3 study.. PubMed. 42(2). 101–107. 1 indexed citations
2.
Heera, Jayvant, Srinivas Rao Valluri, Charles Craig, et al.. (2014). First prospective comparison of genotypic vs phenotypic tropism assays in predicting virologic responses to Maraviroc (MVC) in a phase 3 study: MODERN. Journal of the International AIDS Society. 17(4S3). 19519–19519. 5 indexed citations
3.
4.
Gulick, Roy M., Gerd Fätkenheuer, William D. Hardy, et al.. (2013). Five-Year Safety Evaluation of Maraviroc in HIV-1–Infected Treatment-Experienced Patients. JAIDS Journal of Acquired Immune Deficiency Syndromes. 65(1). 78–81. 31 indexed citations
5.
Lee, Guinevere Q., P. Richard Harrigan, Winnie Dong, et al.. (2013). Comparison of Population and 454 “Deep” Sequence Analysis for HIV Type 1 Tropism Versus the Original Trofile Assay in Non-B Subtypes. AIDS Research and Human Retroviruses. 29(6). 979–984. 14 indexed citations
6.
Swenson, Luke C., Winnie Dong, Theresa Mo, et al.. (2013). Use of Cellular HIV DNA to Predict Virologic Response to Maraviroc: Performance of Population-Based and Deep Sequencing. Clinical Infectious Diseases. 56(11). 1659–1666. 24 indexed citations
7.
Vourvahis, Manoli, et al.. (2013). The Effects of Boceprevir and Telaprevir on the Pharmacokinetics of Maraviroc. JAIDS Journal of Acquired Immune Deficiency Syndromes. 65(5). 564–570. 17 indexed citations
8.
Cooper, David A., Jayvant Heera, Prudence Ive, et al.. (2013). Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1. AIDS. 28(5). 717–725. 30 indexed citations
9.
Lazzarin, Adriano, et al.. (2012). Safety Profile of Maraviroc in Patients Coinfected With HIV-1 and Hepatitis B or C Included in the Maraviroc Expanded Access Program. HIV Clinical Trials. 13(2). 83–89. 12 indexed citations
10.
11.
Mills, Anthony, Donna Mildvan, Daniel Podzamczer, et al.. (2012). Maraviroc Once-Daily Nucleoside Analog-Sparing Regimen in Treatment-Naive Patients. JAIDS Journal of Acquired Immune Deficiency Syndromes. 62(2). 164–170. 30 indexed citations
12.
Swenson, Luke C., Theresa Mo, Winnie Dong, et al.. (2011). Deep V3 Sequencing for HIV Type 1 Tropism in Treatment-Naive Patients: A Reanalysis of the MERIT Trial of Maraviroc. Clinical Infectious Diseases. 53(7). 732–742. 79 indexed citations
13.
Lazzarin, Adriano, Giovanni Di Perri, Juan Sierra‐Madero, et al.. (2011). Maraviroc Can Improve Lipid Profiles in Dyslipidemic Patients with HIV: Results from the MERIT Trial. HIV Clinical Trials. 12(1). 24–36. 42 indexed citations
14.
Wilkin, Timothy, Matthew Bidwell Goetz, Robert Leduc, et al.. (2011). Reanalysis of Coreceptor Tropism in HIV-1-Infected Adults Using a Phenotypic Assay with Enhanced Sensitivity. Clinical Infectious Diseases. 52(7). 925–928. 35 indexed citations
15.
Ayoub, Ayman, James Goodrich, Jayvant Heera, et al.. (2010). Hepatic safety and tolerability in the maraviroc clinical development program. AIDS. 24(17). 2743–2750. 12 indexed citations
16.
Sierra‐Madero, Juan, Giovanni Di Perri, Robin Wood, et al.. (2010). Efficacy and Safety of Maraviroc Versus Efavirenz, Both With Zidovudine/Lamivudine: 96-Week Results From the MERIT Study. HIV Clinical Trials. 11(3). 125–132. 49 indexed citations
17.
Swenson, Luke C., Winnie Dong, Xiaolin Zhong, et al.. (2010). Deep Sequencing to Infer HIV-1 Co-Receptor Usage: Application to Three Clinical Trials of Maraviroc in Treatment-Experienced Patients. The Journal of Infectious Diseases. 203(2). 237–245. 119 indexed citations
18.
Hardy, William D., Roy M. Gulick, Howard Mayer, et al.. (2010). Two-Year Safety and Virologic Efficacy of Maraviroc in Treatment-Experienced Patients With CCR5-Tropic HIV-1 Infection: 96-Week Combined Analysis of MOTIVATE 1 and 2. JAIDS Journal of Acquired Immune Deficiency Syndromes. 55(5). 558–564. 61 indexed citations
19.
Thielen, Alexander, Thomas Lengauer, Luke C. Swenson, et al.. (2010). Mutations in Gp41 are Correlated with Coreceptor Tropism but Do Not Improve Prediction Methods Substantially. Antiviral Therapy. 16(3). 319–328. 20 indexed citations
20.
Madhi, Shabir A., Jayvant Heera, Locadiah Kuwanda, & Keith P. Klugman. (2005). Use of Procalcitonin and C-Reactive Protein to Evaluate Vaccine Efficacy against Pneumonia. PLoS Medicine. 2(2). e38–e38. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Pauline Campa Breakdown of academic impact, for papers by Michael Wohlfeiler Breakdown of academic impact, for papers by Theresa Mo Breakdown of academic impact, for papers by Maria Cecília Araripe Sucupira Breakdown of academic impact, for papers by Mary O’Hearn Breakdown of academic impact, for papers by Moti Ramgopal Breakdown of academic impact, for papers by J Lange Breakdown of academic impact, for papers by Sidonie Lambert-Niclot Breakdown of academic impact, for papers by Anna Cruceta Breakdown of academic impact, for papers by Gilles Darcis
Rankless by CCL
2026